JPRN-UMIN000010743已完成未知
Analysis of immunological status using CFSE-MLR for de-novo kidney transplant recipients who are treated with Everolimus commencing 3 months after surgery. - Analysis of immunological status using CFSE-MLR for kidney transplant recipients treated with Everolimus.
Trasnplantation surgery, Hiroshima University Hospital0 个研究点目标入组 80 人开始时间: 2013年5月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
o significant difference was found between reduced Cyclosporine plus Everolimus group and normal dose Cyclosporine group in CFSE-MLR categorization.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •rejection severe proteinuria
研究者
相似试验
已完成
4 期
Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow upChronic Rejection of Cardiac TransplantNCT00596557Rabin Medical Center20
已完成
3 期
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic RejectionGraft RejectionNCT00300274Novartis Pharmaceuticals721
终止
4 期
Shift to Everolimus (RAD) Kidney Sparing StudyKidney DysfunctionHeart TransplantationNCT00420537University of Bologna34
已完成
4 期
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant RecipientsHeart TransplantationNCT00170859Novartis Pharmaceuticals
已完成
4 期
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant RecipientsRenal FunctionNCT00634920Novartis Pharmaceuticals204